Blog
RSS FeedPosted by Michael Wonder on 07 Oct 2024
Crossing the equity chasm: addressing a second valley of death in biomedical innovation
3 October 2024 - Traditionally, the term valley of death refers to the gap where advancements in basic research fail to ...
Posted by Michael Wonder on 12 Jul 2024
Incorporating real option value in valuing innovation: a way forward
10 July 2024 - Considerable progress has been made in defining and measuring the real option value of medical technologies. ...
Posted by Michael Wonder on 20 Jun 2024
What good are whizzy new drugs if the world can’t afford them?
14 June 2024 - Bringing gene therapies and obesity drugs to the masses will require financial innovation too, says Steven Pearson. ...
Posted by Michael Wonder on 29 May 2024
KRPIA urges incoming Assembly to recognise new drugs’ value
28 May 2024 - The Korean Research based Pharma Industry Association (KRPIA) called for the 22nd National Assembly, which is ...
Posted by Michael Wonder on 24 May 2024
NICE and NHS England announce plan to enable innovative tech to be adopted quicker
23 May 2024 - NHS patients in England will benefit from faster access to the most innovative and cutting-edge medical technologies ...
Posted by Michael Wonder on 07 Mar 2024
Early impact of the Inflation Reduction Act on drug discovery
6 March 2024 - Despite the concerns of the biopharma industry, the Inflation Reduction Act has been enacted and with it, ...
Posted by Michael Wonder on 05 Feb 2024
Be thankful for high drug prices
4 February 2024 - If Americans weren’t overcharged, we wouldn’t have innovative treatments. ...
Posted by Michael Wonder on 01 Jan 2024
New medical treatments will use genetic scissors, and other clever tricks
13 November 2023 - New medicines to treat sickle cell disease and beta thalassaemia, two genetic blood disorders, will make headlines ...
Posted by Michael Wonder on 14 Dec 2023
MHRA supports launch of Innovate UK’s first of its kind initiative to fund new regulatory science and innovation networks
14 December 2023 - Applications are now open for academic institutions wishing to bid for funding to collaborate with others to ...
Posted by Michael Wonder on 08 Dec 2023
Statement from President Joe Biden on FDA approval of gene therapies to treat sickle cell disease
8 December 2023 - As we’ve seen throughout our history, when the US Government invests in innovation, we can achieve breakthroughs ...
Posted by Michael Wonder on 08 Oct 2023
A decade of health innovation: the impact of new medicines on patient health and the implications for NICE’s size of benefit multiplier
6 October 2023 - This study aimed to estimate the incremental health benefits of pharmaceutical innovations approved between 2011 and 2021 ...
Posted by Michael Wonder on 05 Oct 2023
New payment models are needed to finance new advanced treatments
29 September 2023 - Pricing and subsidy methods and processes need to be developed to address the challenges that arise when ...
Posted by Michael Wonder on 12 Sep 2023
The Inflation Reduction Act will lead to fewer new medicines
11 September 2023 - The impact of the Inflation Reduction Act on the biopharmaceutical industry is going to be substantial in ...
Posted by Michael Wonder on 13 Apr 2023
Blocking FDA approval of abortion pill could stifle innovation in the biopharma industry, experts say
13 April 2023 - If courts affirm US District Judge Matthew Kacsmaryk’s decision to suspend the FDA’s approval, it could make ...
Posted by Michael Wonder on 28 Mar 2023
iOnctura awarded UK's MHRA Innovation Passport for entry into innovative licensing and access pathway
28 March 2023 - iOnctura today announces that the innovative medicine designation, the Innovation Passport, has been awarded for roginolisib, ...